CORRESP
   1271 Avenue of the Americas
   New York, New York 10020-1401
   Tel: +1.212.906.1200 Fax: +1.212.751.4864
   www.lw.com   

LOGO

   FIRM / AFFILIATE OFFICES
   Austin    Milan
   Beijing    Munich
   Boston    New York
   Brussels    Orange County
   Century City    Paris
   Chicago    Riyadh

January 29, 2024

   Dubai    San Diego
   Düsseldorf    San Francisco
   Frankfurt    Seoul
   Hamburg    Silicon Valley
   Hong Kong    Singapore
   Houston    Tel Aviv
   London    Tokyo
   Los Angeles    Washington, D.C.

VIA EDGAR

   Madrid   

Division of Corporation Finance

Office of Life Sciences

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549-6010

 

Attention:   

Tyler Howes

Alan Campbell

Michael Fay

Brian Cascio

  

Re:  Fractyl Health, Inc.

Registration Statement on Form S-1

Filed December 14, 2023

File No. 333-276046

To the addressees set forth above:

On behalf of our client, Fractyl Health, Inc. (the “Company”), set forth below is the Company’s response to the comment of the Staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”) in its letter dated December 20, 2023, relating to the Company’s registration statement on Form S-1 filed on December 14, 2023 (the “Registration Statement”).

The Company has filed today Amendment No. 1 to the Registration Statement (“Amendment No. 1”), together with this letter, via EDGAR submission. For convenience of reference, the text of the comment in the Staff’s letter has been reproduced in bold and italics herein. The Company has also provided its response immediately after the comment. Capitalized terms used but not otherwise defined herein have the meanings assigned to such terms in Amendment No. 1.


January 29, 2024

Page 2

 

LOGO

 

Registration Statement on Form S-1

Prospectus Summary

Overview, page 1

 

1.

Please revise to provide the source for your statement that up to two-thirds of patients discontinue weekly GLP-1RA therapy within the first year. In your revisions, please disclose the drugs that were discontinued and the dates covered by the study or studies showing the discontinuation.

Response: In response to the Staff’s comment, the Company has revised the disclosure on pages 1, 101, 122 and 130 of Amendment No. 1.

*********

We hope that the foregoing has been responsive to the Staff’s comment and look forward to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact me at (212) 906-2916 with any questions or further comments you may have regarding this filing or if you wish to discuss the above.

 

Sincerely,

/s/ Nathan Ajiashvili

Nathan Ajiashvili

of LATHAM & WATKINS LLP

Enclosures

cc: (via e-mail)

Harith Rajagopalan, M.D., Ph.D., Chief Executive Officer, Fractyl Health, Inc.

Johan Brigham, Latham & Watkins LLP

Evan Smith, Latham & Watkins LLP

Jonathan Sarna, Latham & Watkins LLP

Edwin O’Connor, Goodwin Procter LLP

Alicia Tschirhart, Goodwin Procter LLP